Free Trial
NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

MoonLake Immunotherapeutics logo
$38.40 -3.50 (-8.35%)
As of 09:39 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

Key Stats

Today's Range
$38.66
$41.53
50-Day Range
$32.83
$42.32
52-Week Range
$31.42
$58.26
Volume
346,528 shs
Average Volume
350,905 shs
Market Capitalization
$2.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$80.50
Consensus Rating
Buy

Company Overview

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

MLTX MarketRank™: 

MoonLake Immunotherapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 756th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MoonLake Immunotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    MoonLake Immunotherapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about MoonLake Immunotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.79) to ($2.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MoonLake Immunotherapeutics is -30.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MoonLake Immunotherapeutics is -30.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MoonLake Immunotherapeutics has a P/B Ratio of 4.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    12.52% of the float of MoonLake Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MoonLake Immunotherapeutics has recently increased by 4.41%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    MoonLake Immunotherapeutics does not currently pay a dividend.

  • Dividend Growth

    MoonLake Immunotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.52% of the float of MoonLake Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MoonLake Immunotherapeutics has recently increased by 4.41%, indicating that investor sentiment is decreasing.
  • News Sentiment

    MoonLake Immunotherapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for MoonLake Immunotherapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    1 people have searched for MLTX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MoonLake Immunotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.02% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MoonLake Immunotherapeutics' insider trading history.
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLTX Stock News Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More Headlines

MLTX Stock Analysis - Frequently Asked Questions

MoonLake Immunotherapeutics' stock was trading at $54.15 at the start of the year. Since then, MLTX stock has decreased by 29.1% and is now trading at $38.40.
View the best growth stocks for 2025 here
.

MoonLake Immunotherapeutics (NASDAQ:MLTX) issued its quarterly earnings results on Wednesday, February, 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.09.

Top institutional investors of MoonLake Immunotherapeutics include Victory Capital Management Inc. (0.40%), Rice Hall James & Associates LLC (0.21%), Harbor Capital Advisors Inc. (0.16%) and Moody Aldrich Partners LLC (0.09%). Insiders that own company stock include Bihua Chen, Da Silva Jorge Santos, Matthias Bodenstedt, Simon Sturge and Kristian Reich.
View institutional ownership trends
.

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MoonLake Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Disc Medicine (IRON), e.l.f. Beauty (ELF), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Arista Networks (ANET).

Company Calendar

Last Earnings
2/26/2025
Today
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MLTX
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$80.50
High Stock Price Target
$104.00
Low Stock Price Target
$66.00
Potential Upside/Downside
+105.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-36,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$8.15 per share
Price / Book
4.82

Miscellaneous

Free Float
56,224,000
Market Cap
$2.51 billion
Optionable
Optionable
Beta
1.31
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:MLTX) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners